Q2 2026 Halozyme Therapeutics, Inc. Earnings Call Transcript
Key Points
- Record total revenue growth of 48% year-over-year to $481 million, driven by robust royalty revenue growth of 50% to $308 million.
- Exceptional pace of new partnerships, signing five new collaboration and licensing agreements (three for ENHANZE, two for Hypercon) in Q2 and July, expanding into new modalities like ADCs and nucleic acids.
- Strong performance from newer launch products (Opdivo SC, Ocrevus SC, Rybrevant SC), with their combined royalty revenue growing 80% quarter-on-quarter, diversifying the revenue stream.
- Raised full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP EPS, reflecting confidence in continued growth.
- Hypercon platform is advancing rapidly, with preparations for first clinical starts in H1 2027 and a projected $1 billion in royalty revenue by the mid-2030s, creating a second growth engine.
- Continued strong performance from established products like DARZALEX SC (18% growth) and VYVGART Hytrulo (143% royalty growth), demonstrating durability.
- Strong financial position with adjusted EBITDA margin over 65% and significant free cash flow, enabling a disciplined capital allocation strategy including $332.8 million in share repurchases in Q2.
- Ongoing legal and patent litigation with Merck regarding the infringement of ENHANZE technology, with an uncertain timeline and outcome in the US.
- Increased R&D expenses (up 58% year-over-year) due to investments in Hypercon and SurfBio, which could pressure near-term margins.
- Potential competitive threat from Alteogen, although Halozyme notes that many companies seeking Alteogen deals have targets exclusively licensed to Halozyme.
- The company's future growth is heavily dependent on the success of partner products, which are subject to clinical trial risks, regulatory approvals, and commercial adoption.
- Guidance for the second half of 2026 implies a significant sequential step-up in royalty revenue, which may be challenging to achieve if new product launches underperform.
- The company is not currently pursuing M&A, focusing on organic growth, which may limit opportunities for external innovation or portfolio expansion in the near term.
Good afternoon. My name is Joel, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's second quarter 2026 financial and operating results conference call. (Operator Instructions) Please note, this event is being recorded.
I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations.
Please go ahead.
Thank you, operator. Good afternoon, and welcome to our Second Quarter 2026 Financial and Operating Results Conference Call.
In addition to the press release issued today after the market close, you could find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Darren Snellgrove, our Chief Financial Officer, will review our financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
